AlanLohHoMD

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Ho

Dr. Alan Ho is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and New York-Presbyterian Hospital. He received his medical degree from Washington University in St. Louis School of Medicine and has been in practice 14 years. Dr. Ho accepts several types of health insurance, listed below. He is one of 62 doctors at NYC Health + Hospitals / Bellevue and one of 370 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(231) 674-7738

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Washington University in St. Louis School of MedicineClass of 2003

Certifications & Licensure

NY State Medical License 2004 - 2026
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 Start of enrollment: 2009 Sep 01
Completed
Not Applicable
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Start of enrollment: 2010 Aug 01
Completed
Phase 2
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Start of enrollment: 2015 Sep 24
COMPLETED
PHASE2
Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
COMPLETED
PHASE2
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers with the BRAF Inhibitor Vemurafenib: a Pilot Study Start of enrollment: 2014 May 20
COMPLETED
NA
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Start of enrollment: 2014 Aug 14
ACTIVE_NOT_RECRUITING
PHASE2
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
New MRI Biomarkers in Head and Neck Cancers Start of enrollment: 2018 Mar 16
RECRUITING
Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Start of enrollment: 2020 Jun 02
ACTIVE_NOT_RECRUITING
PHASE2
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Start of enrollment: 2020 Sep 02
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Start of enrollment: 2020 Jun 26
COMPLETED
PHASE1
Roles: Principal Investigator, Contact
A Study of Avutometinib and Defactinib in People With Thyroid Cancer Start of enrollment: 2023 Aug 16
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers Start of enrollment: 2023 Jul 20
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer Start of enrollment: 2023 Feb 07
Recruiting
Roles: Contact
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 Start of enrollment: 2023 Mar 08
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Targeted RNA sequencing in diagnostically challenging head and neck carcinomas identifies novel MON2::STAT6, NFATC2::NUTM2B, POC5::RAF1, and NSD3::NCOA2 gene fusions.
Ying-Hsia Chu, Nora Katabi, Purvil Sukhadia, Kerry A Mullaney, Michael Zaidinski
Histopathology. 2025-04-01
1 citations
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.
Gabrielle Knafler, Alan L Ho, Kathleen N Moore, Seth M Pollack, Jean-Marc Navenot
Cancer Treatment Reviews. 2025-03-01
1 citations
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2025-02-18

Journal Articles

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Steven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
Multi-Dimensional Genomic Analysis of Myoepithelial Carcinoma Identifies Prevalent Oncogenic Gene Fusions
Ian Ganly, Alan L Ho, Ronald Ghossein, Nadeem Riaz, Cristina R Antonescu, Nora Katabi, Nature

Lectures

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck CancerOctober 30th, 2024
Long-Term Follow-up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options for Recurrent or Metastatic HNSCCOctober 14th, 2022
Enzalutamide in Advanced Androgen Receptor-Positive Salivary Gland CancerAugust 4th, 2022
Join now to see all

Grant Support

Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancersSLOAN-KETTERING INST CAN RESEARCH2024–2028
Improving efficacy of radioiodine treatment of thyroid cancerSLOAN-KETTERING INST CAN RESEARCH2021–2026

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment